Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification

Human Pathology

Volumn 45, Issue 10, 2014, Pages 2136-2143

  Park, Kyung ^a   Chen, Zhengming ^a   Macdonald, Theresa Y ^a   Siddiqui, Javed ^b,c   Ye, Huihui ^d,e   Erbersdobler, Andreas ^f   Shevchuk, Maria M ^a   Robinson, Brian D ^a,g   Sanda, Martin G ^d,e   Chinnaiyan, Arul M ^b,c   Beltran, Himisha ^a,g   Rubin, Mark A ^a,g   Mosquera, Juan Miguel ^a,g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g Department of Obstetrics Gynecology   (United States)

Author keywords

AURKA amplification; MYCN amplification; Neuroendocrine differentiation; Paneth cell like; Prostate cancer

Indexed keywords

AURORA A KINASE; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; AURKA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL GRANULE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MUTATION; NEUROENDOCRINE TUMOR; PANETH CELL; PERINEURAL INVASION; PROSTATE CANCER; PROSTATECTOMY; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CELL DIFFERENTIATION; FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AURORA KINASE A; CELL DIFFERENTIATION; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PANETH CELLS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908161866     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.06.008     Document Type: Article

References (17)

1. Y. Sun, J. Niu, and J. Huang Neuroendocrine differentiation in prostate cancer Am J Transl Res 1 2009 148 162
2. J.M. Mosquera, H. Beltran, and K. Park Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer Neoplasia 15 2013 1 10
3. D. Hirano, Y. Okada, S. Minei, Y. Takimoto, and N. Nemoto Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy Eur Urol 45 2004 586 592 [discussion 592]
4. T. Ito, S. Yamamoto, and Y. Ohno Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence Oncol Rep 8 2001 1221 1224
5. H. Beltran, D.S. Rickman, and K. Park Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets Cancer Discov 1 2011 487 495
6. H. Beltran, S.T. Tagawa, and K. Park Challenges in recognizing treatment-related neuroendocrine prostate cancer J Clin Oncol 30 2012 e386 e389
7. A.M. Aparicio, A.L. Harzstark, and P.G. Corn Platinum-based chemotherapy for variant castrate-resistant prostate cancer Clin Cancer Res 19 2013 3621 3630
8. M.G. Weaver, F.W. Abdul-Karim, J. Srigley, D.G. Bostwick, J.Y. Ro, and A.G. Ayala Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study Am J Surg Pathol 16 1992 62 68
9. J. Haratake, A. Horie, and K. Ito Argyrophilic adenocarcinoma of the prostate with Paneth cell-like granules Acta Pathol Jpn 37 1987 831 836
10. J.I. Epstein, M.B. Amin, and H. Beltran Proposed morphologic classification of prostate cancer with neuroendocrine differentiation Am J Surg Pathol 38 2014 756 767
11. E.F. Tamas, and J.I. Epstein Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate Am J Surg Pathol 30 2006 980 985
12. R. Esgueva, K. Park, and R. Kim Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium Diagn Mol Pathol 21 2012 61 68
13. M.F. Berger, M.S. Lawrence, and F. Demichelis The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
14. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
15. S. Perner, F. Demichelis, and R. Beroukhim TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer Cancer Res 66 2006 8337 8341
16. J.M. Mosquera, R. Mehra, and M.M. Regan Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States Clin Cancer Res 15 2009 4706 4711
17. H. Adlakha, and D.G. Bostwick Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases Hum Pathol 25 1994 135 139